MassDevice.com +5 | The top 5 medtech stories for August 8, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Why the medtech contract manufacturing M&A trend isn’t slowing down Consolidation is increasingly shaping the medical device industry, but what about players on the other side of the fence? Medtech contract manufacturing partners to OEMs are seeing their own abundance of M&A as larger players look to expand their influence and keep up with increasing demand. Read more   4. Rebiotix launches late-stage superbug trial for microbiome-based drug Rebiotix isn’t a traditional drugmaker. Its products are alive. The 32-person company, based in Roseville, Minn., is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes. Read more 3. Aum Cardiovascular wins FDA clearance for Cadence heart device Aum Cardiovascular said today that it won 510(k) clearance from the FDA for its Cadence device, which is designed to detec...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog News Well Plus 5 Source Type: news